All In Biotech

Drug Trial Radar · NCT06271265

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery

Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Mar 29, 2024

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Pacira Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Feb 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

Conditions

  • Postoperative Pain

Interventions

  • EXPARELDrug

    A single dose of EXPAREL Injectable Product via LIA

  • bupivacaineDrug

    A single dose of 0.25% bupivacaine via LIA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The following model-predicted PK endpoint will be determined:Time frame: through 72 hours
  2. The following model-predicted PK endpoint will be determined:Time frame: through 72 hours
  3. The following model-predicted PK endpoint will be determined:Time frame: through 72 hours
  4. The following model-predicted PK endpoint will be determined:Time frame: through 72 hours
  5. The following model-predicted PK endpoint will be determined:Time frame: through 72 hours
  6. The following model-predicted PK endpoint will be determined:Time frame: through 72 hours

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana University Health, Riley Hospital For Children

    Indianapolis, Indiana · Recruiting

  • St. Louis Children's Hospital (SLCH)

    St Louis, Missouri · Recruiting

  • Duke University Health System

    Durham, North Carolina · Recruiting

  • University of Oklahoma (OU) - Medical Center - The Children's Hospital

    Oklahoma City, Oklahoma · Recruiting

  • The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.